Bolt Biotherapeutics director granted 5,000 stock options

Bolt Biotherapeutics director Brian O’Callaghan received a grant of stock options covering 5,000 shares of common stock.

Rhea-AI Filing Summary

Bolt Biotherapeutics director Brian O’Callaghan received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $4.43 per share and expire on June 9, 2036. Following this grant, he holds options on 5,000 shares.

The options will vest on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, as long as he remains in continuous service. They also vest in full if there is a change in control of Bolt Biotherapeutics.

Insights

Equity compensation analyst

Routine director option grant with service- and change-in-control-based vesting.

The filing shows Brian O’Callaghan, a director of Bolt Biotherapeutics, receiving stock options for 5,000 shares at an exercise price of $4.43 per share, expiring on June 9, 2036. This is classified as a grant/award, not a market purchase or sale.

The options vest on the earlier of June 9, 2027 or just before the next annual stockholder meeting, contingent on continuous service. They also vest in full upon a change in control, a common protection feature for directors. With no sales or exercises reported and only 5,000 option shares shown after the transaction, this appears to be a standard, small-scale component of director compensation.

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider O'CALLAGHAN BRIAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

Key Figures

Option shares granted: 5,000 shares Exercise price: $4.43 per share Total options after grant: 5,000 shares +2 more

5 metrics

Option shares granted 5,000 shares Stock Option (Right to Buy) grant

Exercise price $4.43 per share Conversion/exercise price of options

Total options after grant 5,000 shares Total derivative securities following transaction

Option expiration June 9, 2036 Expiration date of stock option

Service-based vesting date June 9, 2027 Latest standard vesting date, subject to continuous service

Key Terms

Stock Option (Right to Buy), exercise price, change in control, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.4300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"the option will vest in full upon a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders financial

"the day immediately prior to the next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service through such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Brian O’Callaghan receive in this Bolt Biotherapeutics (BOLT) Form 4?

Brian O’Callaghan received a stock option grant for 5,000 shares of Bolt Biotherapeutics common stock. The option allows him to buy shares at an exercise price of $4.43 per share, with an expiration date of June 9, 2036, if vesting conditions are met.

What is the exercise price and expiration for the BOLT stock options granted to Brian O’Callaghan?

The stock options granted to Brian O’Callaghan carry an exercise price of $4.43 per share. They expire on June 9, 2036, giving him a long window to exercise the options once they vest, assuming he continues to meet all service conditions.

When do Brian O’Callaghan’s Bolt Biotherapeutics (BOLT) options vest?

The options vest on the earlier of June 9, 2027 or the day immediately before Bolt Biotherapeutics’ next annual stockholder meeting. Vesting is contingent on his continuous service, and the options provide long-term alignment with shareholder interests under these conditions.

How many Bolt Biotherapeutics (BOLT) option shares does Brian O’Callaghan hold after this grant?

After this grant, Brian O’Callaghan holds options for 5,000 shares of Bolt Biotherapeutics common stock. The Form 4 reports 5,000 derivative securities following the transaction, indicating this grant establishes or updates his option position at that level.

What happens to Brian O’Callaghan’s BOLT options if there is a change in control?

If there is a change in control of Bolt Biotherapeutics, the option will vest in full. This acceleration provision means all 5,000 underlying shares could become exercisable at once upon such a corporate event, enhancing protection for the director’s equity award.

Is Brian O’Callaghan buying or selling Bolt Biotherapeutics (BOLT) stock in this Form 4?

This Form 4 does not show a market buy or sell of Bolt Biotherapeutics stock. It reports a grant of stock options, classified as an acquisition award, giving him the right to purchase 5,000 shares later at $4.43 per share if he chooses to exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'CALLAGHAN BRIAN

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.43	06/10/2026		A		5,000		(1)	06/09/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

	/s/ William P. Quinn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)